Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DYNAVAX TECHNOLOGIES CORP Director's Dealing 2023

Aug 10, 2023

32130_dirs_2023-08-10_4bfd5028-0d85-4183-84ae-29b2cb0cc952.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DYNAVAX TECHNOLOGIES CORP (DVAX)
CIK: 0001029142
Period of Report: 2023-08-08

Reporting Person: Novack David F (President & COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-08-08 Common Stock M 25000 $3.81 Acquired 28187 Direct
2023-08-08 Common Stock M 15000 $5.42 Acquired 43187 Direct
2023-08-08 Common Stock S 10000 $14.74 Disposed 33187 Direct
2023-08-08 Common Stock S 10000 $14.73 Disposed 23187 Direct
2023-08-08 Common Stock S 20000 $15.01 Disposed 3187 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-08-08 Stock Option (Right to Buy) $3.81 M 25000 Disposed 2026-06-13 Common Stock (25000) Direct
2023-08-08 Stock Option (Right to Buy) $5.42 M 15000 Disposed 2027-02-11 Common Stock (15000) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on May 5, 2023.

F2: This transaction was executed in multiple trades at prices ranging from $14.63 to $14.83; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax

F3: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.01; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.

F4: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of June 14, 2019, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter, providing further that the options are subject to approval by our stockholders of an increase in the number of shares available under the 2018 Equity Incentive Plan.

F5: Not applicable.

F6: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12, 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter, providing further that the options are subject to approval by our stockholders of an increase in the number of shares available under the 2018 Equity Incentive Plan.